Venus Remedies bags Kenyan GMP certification for all its Baddi production facilities

Hailing this achievement, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, said, “This GMP certification validates our relentless pursuit of excellence and further strengthens our position as a leading manufacturer of fixed-dosage injectables. It paves the way for consolidating our position in Kenya and other African markets as part of our global expansion plans.”

The GMP from Kenya, estimated to be a $780 million market, is set to bolster the expansion of Venus Remedies in the COSMEA (Common Market for Eastern and Southern Africa) region, of which Kenya is a key member, and subsequently the entire African pharmaceutical market, which is estimated to be worth $7.3-billion. The company has a presence in Uganda, Tanzania, Kenya and Rwanda countries in Africa, where the pharmaceutical market is expected to grow upto $2.8 billion by year 2023 at a CAGR of 10% approx.

Akshansh Chaudhary, Executive Director, Venus Remedies, said the company will leverage this certification to bring it diverse range of high-quality products to the Kenyan and other African markets, thus making a positive impact on healthcare in the region. “This achievement is aligned with our vision of improving global health and reinforces our commitment to delivering excellence in pharmaceutical manufacturing," he said.

The GMP certification awarded by Kenya comes just three months after the company secured a GMP approval from Saudi Arabia, which is expected to speed up the process of marketing authorisations for the company’s products in Gulf Cooperation Council (GCC) and Middle East and North Africa (MENA) regions.